Lpath, Inc.

Tosk, Incorporated

Biocheck, Inc.

Angiogenex, Inc.

Angiogeney, Inc.

University of California

William A Garland

Roger A Sabbadini

Genevieve Hansen

Brian D Frenzel

Steven Tarran Jones

David Gareth Williams

Philip Liaw

Travis Karg

Stephen D Yanofsky

Solomon B Ungashe

Annie L Lennek

Jung-Shou Chen

Glenn L Stoller

James Stephen Swaney

Gordon B Mills

Jonathan Michael Wojciak

Marina Safonov

Scott R Pancoast

Rosalia Matteo

Jaideep Chaudhary

Amy L Cavalli

Heshan Peiris

Steve Yanofsky

Joseph Konopelski

Todd Wipke

Methods for reducing radiation therapy induced toxicity, e.g., mucositis, in a subject are provided. Aspects of the methods include administering an effective amount of a radiation toxicity-reducing adjuvant to the subject. In certain embodiments, the radiation toxicity-reducing adjuvant is a 2,2'-anhydropyrimidine, or a derivative thereof. Also provided are compositions for use in practicing the subject methods. The subject methods and compositions find use in a variety of different applications, including the treatment of a variety of different disease conditions.

Methods and compositions for reducing radiation induced toxicity

RAS modulating compounds and methods of using the same are provided. The compounds find use in modulating the activity of a target RAS in a sample. The target RAS can be a mutant RAS that is implicated in a disease of interest. In some cases, the subject compounds can inhibit the growth of cancer cells whose progression is driven by kRAS or a mutated kRAS. Methods of treating a subject for a RAS driven disease including administering a therapeutically effective amount of the subject compound are provided. Also provided are pharmaceutical compositions and kits which include the subject compounds.

Modulators of RAS GTPase

Methods for improving the therapeutic effectiveness of uridine administered to prevent and/or reduce various maladies including adverse event from drugs are provided. Aspects of the methods include administering an effective amount of a uridine maximizing adjuvant, e.g., a 2,2'-anhydropyrimidine, or a derivative thereof, to the subject. Also provided are compositions for use in practicing the subject methods. The subject methods and compositions find use in a variety of different applications, including the treatment of a variety of different disease conditions.

Methods and compositions for maximizing the prevention and/or reduction of various maladies and drug side-effects using uridine

The present invention relates to compositions, formulations, and methods for treating pulmonary disorders having fibrosis as part of the underlying pathology, such as IPF and ARDS, by administration of a UPase inhibitor, with or without supplemental UR, a UR prodrug, or a UR mimetic to a subject in need thereof.

Uridine phosphorylase inhibitors to treat or prevent pulmonary disease

Methods for treating a subject for mucositis are provided. Aspects of the methods include administering an effective amount of a cancer therapy toxicity-reducing adjuvant in combination with uridine or a prodrug thereof to the subject. In certain embodiments, the cancer therapy toxicity-reducing adjuvant is a 2,2'-anhydropyrimidine, or a derivative thereof. Also provided are compositions for use in practicing the subject methods. The subject methods and compositions find use in a variety of different cancer therapy applications.

Methods and compositions for treating mucositis

Methods of treating a subject for a liver condition, e.g., NAFLD, NASH, and/or DILI, are provided. Aspects of the methods include administering to the subject an effective amount of a UPase inhibitor, optionally in combination with a uridine active agent (e.g., uridine (UR), a UR pro-drug or a UR mimetic), such as supplemental uridine, to treat the subject for the liver condition. Also provided are compositions for use in practicing the subject methods.

Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions

Pyrazolopyrimidine RAS modulating compounds and methods of using the same are provided. The pyrazolopyrimidine compounds find use in modulating the activity of a target RAS in a sample. The target RAS can be a mutant RAS that is implicated in a disease of interest. In some cases, the subject compounds can inhibit the growth of cancer cells whose progression is driven by kRAS or a mutated kRAS. Methods of treating a subject for a RAS driven disease including administering a therapeutically effective amount of the subject compound are provided. Also provided are pharmaceutical compositions and kits which include the subject compounds.

Pyrazolopyrimidine modulators of RAS GTPase

Methods are provided for using methotrexate (MTX) active agents in which reduced host toxicity is observed. Aspects of the methods include administering to a subject an effective amount of an MTX active agent in conjunction with a MTX toxicity-reducing adjuvant, such as a 2,2'-anhydropyrimidine, a derivative thereof or a uridine phosphorylase inhibitor. Also provided are compositions and kits that find use in practicing embodiments of the invention. The methods and compositions find use in a variety of applications, including the treatment of a variety of different disease conditions.

Methotrexate adjuvants to reduce toxicity and methods for using the same

Non-mammalian, transgenic animals, e.g., flies, that include a RAS transgene, are provided. Also provided are methods of using the subject transgenic non-mammalian animals to identify compounds having activity with respect to cellular proliferative, such as neoplastic, diseases.

Non-mammalian RAS transgenic animal model

Methods are provided for using doxorubicin active agents in which reduced host toxicity is observed. Aspects of the methods including administering to a subject an effective amount of a doxorubicin active agent in conjunction with a doxorubicin toxicity-reducing adjuvant, e.g., a nitrone compound, or a nitrone compound in combination with a bisdioxopiperazine compound. Also provided are compositions for use in practicing the subject methods. The methods and compositions find use in a variety of different applications, including in the treatment of a variety of different disease conditions.

Doxorubicin adjuvants to reduce toxicity and methods for using the same

Compositions and methods for producing monoclonal antibodies and their derivatives reactive against bioactive lipid targets are described. These compositions include derivatized lipids, each of which comprises a bioactive lipid that having a polar head group and at least one hydrocarbon chain (e.g., a lysolipid such as lysophosphatidic acid or sphingosine-1-phosphate) in which a carbon atom has been derivatized with a pendant reactive group; immunogens made by linking a derivatized lipid to a carrier moiety (e.g., a carrier protein, polyethylene glycol, colloidal gold, alginate, or a silicone bead); monoclonal antibodies and derivatives produced by immunizing an animal with such an immunogen; and therapeutic and diagnostic compositions containing such antibodies and antibody derivatives. Methods for making such derivatized lipids, immunogens, and monoclonal antibodies and derivatives, methods for detecting such antibodies once generated, and therapeutic and diagnostic methods for using such antibodies and derivatives, are also described.

Methods and reagents for detecting bioactive lipids

Immune-derived moieties reactive against lysophosphatidic acid

The present invention relates to compositions that comprise an anti-S1P monoclonal antibody, antibody fragment, or derivative in a carrier, particularly a buffered, hypertonic aqueous solution, as well as to kits containing such compositions, and methods for using such compositions for treatment of diseases and conditions associated with S1P.

Growing community of inventors

San Clemente, CA, United States of America

William A Garland